Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPhysiomics Regulatory News (PYC)

Share Price Information for Physiomics (PYC)

Share Price is delayed by 15 minutes
Get Live Data
0.625    -0.025 (-3.85%)
Bid:
0.60
Ask:
0.65
Spread: 0.05 (8.333%)
Market Cap: £2.83m
PYC Live PriceLast checked at - London Stock Exchange

Intraday Physiomics Share Chart

Director/PDMR Shareholding

18 Oct 2005 12:06

Acquisition of shares by CEO Oxford, UK, 18 October 2005 The Board of Physiomics plc (AIM:PYC), a Europeansystems biology simulation company, was informed on 17 October that Dr JohnSavin, CEO, has paid, with the agreement of the Board, in cash for 54,688shares at 2p per share. These shares were issued in December 2004 in respect ofa small overcharge of third party flotation costs.Dr Savin's shareholding has increased to 604,688 ordinary shares of 0.04pcomprising 0.26% of the Company's issued share capital. --ENDS- For further information please contact: Physiomics plcMr David Evans (Chairman) Tel: 07740 084452Dr John Savin (CEO) Tel: 01865 784981 Northbank Communications Tel: 020 7886 8150Emma Palmer (financial enquiries)Fiona Brown/Rowan Minnion (media enquiries)Notes to EditorsPhysiomics plcPhysiomics plc (AIM:PYC) is a systems biology company applying computer-basedsimulations of cell behaviour in drug development, aimed at reducing the highcost and attrition rates of clinical trials. As 80-90 per cent of all clinicaldrug candidates fail to reach the market, estimates show even a ten per cent.overall improvement in success rates could reduce the cost of one drug'sdevelopment by up to $242 million, from the current estimate of around $800million.Physiomics is currently focused on optimising the design of cancer clinicaltrials as a service to major pharmaceutical companies. In addition, it hassecured an option to in-license two innovative molecules in the cancer areafrom Cronos therapeutics.Physiomics has a major collaboration with BayerTechnology Services GmbH to develop globally clinical response predictionservices using both companies' proprietary technologies and mathematical cellmodels, including the SystemCell‚® technology developed by Physiomics. In June2005, Physiomics became is a distributor of Bayer's PK-Sim‚® product forunderstanding the way pharmaceuticals are distributed round the body.Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in2004.For further information, please visit www.physiomics-plc.comSystemCell is a registered trademark of Physiomics plcPHYSIOMICS PLC
Date   Source Headline
28th May 20267:00 amRNS-RHantavirus Translational Modelling Capability
27th May 20267:00 amRNSPhysiomics Awarded Multiple Contract Awards
26th May 20263:48 pmRNSHolding(s) in Company
21st May 20265:21 pmRNSHolding(s) in Company
15th May 20267:00 amRNSUpdate regarding CEO - Peter Sargent
12th May 20267:00 amRNSAppointment of Stewart Williams as Consultant
8th May 20267:00 amRNSStrategy Update
29th Apr 20266:15 pmRNSReplacement Result of Meeting and Board Changes
29th Apr 202611:00 amRNSResults of General Meeting and Board Changes
24th Apr 202610:30 amRNSReminder to Vote Against Resolutions
22nd Apr 20267:00 amRNSLaunch of Website for Requisitioned Meeting
17th Apr 20267:00 amRNSISS Voting Recommendation
14th Apr 20267:00 amRNSPhysiomics Awarded New Contract by Numab
8th Apr 20267:00 amRNSRequestioned GM and Investor Presentation
20th Mar 20269:45 amRNSHolding(s) in Company
20th Mar 20267:00 amRNSCancellation of General Meeting
18th Mar 20262:55 pmRNSResult of WRAP Retail Offer
17th Mar 20267:01 amRNSWRAP Retail Offer for up to £110,000.00
17th Mar 20267:01 amRNSWRAP Retail Offer for up to £110,000.00
17th Mar 20267:00 amRNSCompletion of Placing and WRAP Retail Offer Launch
17th Mar 20267:00 amRNSCompletion of Placing and WRAP Retail Offer Launch
16th Mar 20267:00 amRNSGeneral Meeting Request
16th Mar 20267:00 amRNSGeneral Meeting Request
13th Mar 20267:00 amRNSResult of WRAP Retail Offer
13th Mar 20267:00 amRNSResult of WRAP Retail Offer
11th Mar 20268:00 amRNSHolding(s) in Company
10th Mar 20267:01 amRNSWRAP Retail Offer for up to £49,999.98
16th Feb 20268:37 amRNSInterim Results
13th Feb 20262:23 pmRNSHolding(s) in Company
12th Feb 20267:00 amRNS-RPhysiomics Awarded New Contract
2nd Feb 202611:40 amRNSHolding(s) in Company
28th Jan 20267:00 amRNSPhysiomics Awarded New Contract by Numab
23rd Dec 20257:00 amRNSOptions Award
23rd Dec 20257:00 amRNSOptions Award
15th Dec 20257:00 amRNSPhysiomics Awarded Follow On Contract by UK Client
11th Dec 20257:00 amRNSPhysiomics Awarded New Contract by Numab
10th Dec 20257:00 amRNS-RPhysiomics Awarded New Contract by GARDP
8th Dec 20254:31 pmRNSHolding(s) in Company
4th Dec 20257:00 amRNS-RPhysiomics Awarded Two New Contracts
3rd Dec 20257:00 amRNSBoard Changes
18th Nov 20253:43 pmRNSResult of AGM
17th Oct 20257:00 amRNSNotice of AGM
30th Sep 20257:00 amRNSChange of Registered Office
29th Sep 20257:00 amRNSAnnual Financial Report
22nd Sep 20257:00 amRNSNotice of Results and Investor Presentation
6th Aug 20257:00 amRNSFollow-on Contract with UK Biotech Client
16th Jul 20257:00 amRNSContract Award
14th Jul 20257:00 amRNSTrading Update
10th Jul 20257:00 amRNSPlatform Implementation and Partnership Expansion
1st Jul 20257:00 amRNSContract Award

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.